JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
This study is assessing the combination of well known cytotoxics with a novel anti-cancer
agent that could be administered as monotherapy without renal toxicity in patients with renal
impairment presenting with advanced or metastatic urothelial carcinoma previously treated
with a platinum-based regimen. The intent of this study is to clarify the benefit/risk ratio
of the two most promising associations of cytotoxics including the novel therapeutic agent,
vinflunine: vinflunine-gemcitabine and vinflunine-carboplatin.